|
Healthcare Headlines |
|
Multiple Sclerosis News From Medical News Today
|
-
Multiple Sclerosis Trust Stresses The Importance Of Reliable Health Information
The recent publication of a booklet about unproven treatments by the Sense About Science campaign group highlights the importance of reliable information for people with MS when making choices about treatments. The booklet I've got nothing to lose by trying it aims to help readers identify false claims of new 'wonder-drugs' and to promote an understanding of good science.
-
Relapsing-Remitting Multiple Sclerosis - Teva Completes Enrollment In Laquinimod Phase III Clinical Trial
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the Phase III clinical trial, Allegro, in relapsing-remitting multiple sclerosis (RRMS). The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound, laquinimod, versus placebo in the treatment of RRMS.
-
Environment Causes Increase In Multiple Sclerosis Among Women Only
Gender has become a dominant factor in Multiple Sclerosis (MS) during the last decades. Already with a ratio of 3.2 to 1 MS is gradually changing into a disease predominantly among women. Since genetic factors can be ruled out as a cause of this gender related increase, scientific attention is on environmental factors that may increase MS risk in women exclusively. Most likely environmental factors include smoking, viral infections, Vitamin D deficiency, hygiene changes and dietary factors.
-
Nutra Pharma Announces Provision Of RPI-78M Under Compassionate Release To Adrenomyeloneuropathy (AMN) Patients
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, will provide RPI-78M under compassionate release to patients previously enrolled in the Phase IIb/IIIa clinical study of Adrenomyeloneuropathy (AMN).
-
Sheffield Hallam University (UK) Explores Exercise Intervention For Multiple Sclerosis Sufferers
Sheffield Hallam University has been awarded a new £200,000 research grant to investigate the effects of exercise intervention on sufferers of multiple sclerosis (MS). The MS Society has awarded the grant to the University's Centre for Sport and Exercise Science, which will study the effects of exercise therapy on physical activity and health outcomes in people living with MS.
-
Multiple Sclerosis 'barometer' Reveals Wide Variation In Care Across Europe
Brussels, 13 November 2008: Patients with multiple sclerosis (MS) in different countries in the Europe face huge variations in provision of treatment and care, according to results from an MS barometer reported at the European parliament. The MS barometer is a benchmarking initiative being carried out by the European Multiple Sclerosis Platform (EMSP), an umbrella organisation of national MS societies.
-
Nerve Cells Need Their Armor In The War Against Diseases
In a new study, researchers at the Montreal Neurological Institute (MNI), McGill University, and the Université de Montréal have discovered an essential mechanism for the maintenance of the normal structure of myelin, the protective covering that insulates and supports nerve cells (neurons). Up until now, very little was known about myelin maintenance.
-
Intraspinal Implant Of Mesenchymal Stem Cells May Not Heal The Demyelinated Spinal Cord
Multiple sclerosis is a disease caused by the loss of the myelinated sheath surrounding the nerve fibers of the spinal cord. Therapeutic hope for curing multiple sclerosis and other demyelinating diseases has included the possibility that stem cell transplants could help remyelinate the spinal cord.
-
Actelion's First-in-class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development
Actelion Ltd (SWX: ATLN) announced that Actelion and Roche have jointly agreed that preclinical and clinical data support progressing Actelion's S1P1 receptor agonist into Phase II clinical development. An update will be presented at Actelion Day 2009, an event held at Actelion's headquarters in Allschwil on 19 February 2009. This event will be a combination of Actelion's annual Media and Analyst Conference and its Research and Development Day.
-
MS Commissioning Pathway, UK
The MS Trust is delighted that the new MS commissioning pathway has been made available via the Department of Health website. The MS Trust has launched the Pathway designed to simplify the process and enable commissioners to provide effective MS services. Successful management of multiple sclerosis requires input from both specialist neurology staff within the secondary sector as well as ongoing support from the primary care teams.
|
|
